Summit Therapeutics released updated follow-up survival data for ivonescimab in a form of non-small cell lung cancer and outlined how outcomes may differ between Western and Asian patient groups. The FDA’s approval decision is scheduled for Nov. 14 for the indication. The data update arrives as the company continues to seek context around durability and baseline comparability across geographies.